Status:

COMPLETED

Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19

Lead Sponsor:

Brigham and Women's Hospital

Collaborating Sponsors:

National Institute on Aging (NIA)

Conditions:

Covid19

Vaccine Refusal

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are...

Eligibility Criteria

Inclusion

  • Patients in the Mass General Brigham system
  • Aged 18 and older
  • Are eligible for the COVID booster vaccine but have not received a dose at time of upcoming primary care clinic visit

Exclusion

  • Documented allergy to a COVID vaccine or its components
  • Home address outside of Massachusetts
  • Did not receive full set of primary COVID-19 vaccination series

Key Trial Info

Start Date :

February 18 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 17 2022

Estimated Enrollment :

3671 Patients enrolled

Trial Details

Trial ID

NCT04871776

Start Date

February 18 2022

End Date

August 17 2022

Last Update

January 16 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mass General Brigham

Boston, Massachusetts, United States, 02120